Nerve Block for Long COVID
(DSBLongCOVID Trial)
Trial Summary
What is the purpose of this trial?
This trial is testing stellate ganglion blocks, which involve injecting a numbing medicine near nerves in the neck. The treatment aims to help patients with long COVID who have ongoing symptoms that don't respond to usual treatments. By blocking nerve signals, it may reduce pain and other issues linked to overactive nerves. Stellate ganglion block (SGB) is an anesthetic treatment initially used for pain relief and has shown promise in treating severe and chronic PTSD.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are currently using anticoagulants (blood thinners).
What data supports the effectiveness of the treatment Stellate Ganglion Block with 0.5% Bupivacaine for Long COVID?
Is the stellate ganglion block generally safe for humans?
Stellate ganglion block is generally considered safe, but rare complications can occur, such as seizures, breathing problems, and a condition called 'locked-in syndrome' where a person is conscious but cannot move or speak. These complications are usually due to incorrect injection, so careful monitoring and preparation are important during the procedure.678910
How is the stellate ganglion block treatment for Long COVID different from other treatments?
The stellate ganglion block (SGB) treatment for Long COVID is unique because it involves injecting a local anesthetic, bupivacaine, near a nerve cluster in the neck to potentially relieve symptoms. This approach is different from other treatments as it targets the sympathetic nervous system, which may help with conditions like chronic pain and Long COVID, where standard treatments are not well-established.345611
Research Team
Jonathann Kuo, MD
Principal Investigator
Medical Director
Eligibility Criteria
This trial is for adults who've had COVID-19 and are now suffering from long-term symptoms like low blood pressure, digestive issues, or pain. They must have confirmed past COVID-19 with a test and ongoing symptoms for at least four weeks. People can't join if they're on blood thinners, have glaucoma, previous similar treatments, local anesthetic allergies, are pregnant, or have infections/masses where the injection would go.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Dual Sympathetic Blocks of the stellate ganglion, performed at 0 and 1 weeks
Follow-up
Participants are monitored for changes in autonomic symptoms and patient-reported outcomes using PROMIS-29 and COMPASS-31 surveys
Treatment Details
Interventions
- Stellate Ganglion Block with 0.5% Bupivacaine
Find a Clinic Near You
Who Is Running the Clinical Trial?
Megan Nicklay
Lead Sponsor
Jonathann Kuo, MD
Lead Sponsor